Sintx Technologies Croissance future

Future contrôle des critères 1/6

Sintx Technologies's earnings are forecast to decline at 30% per annum while its annual revenue is expected to grow at 7.6% per year. EPS is expected to decline by 156.1% per annum.

Informations clés

-30.0%

Taux de croissance des bénéfices

-156.13%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	13.3%
Taux de croissance des recettes	7.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	20 Jun 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

DB:1110 - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	3	-14	N/A	-11	2
12/31/2024	3	-12	N/A	-11	2
6/30/2024	3	-9	-12	-11	N/A
3/31/2024	3	-9	-12	-12	N/A
12/31/2023	3	-8	-15	-14	N/A
9/30/2023	2	-14	-14	-13	N/A
6/30/2023	2	-14	-14	-13	N/A
3/31/2023	2	-14	-13	-12	N/A
12/31/2022	2	-16	-12	-10	N/A
9/30/2022	1	-10	-12	-11	N/A
6/30/2022	1	-10	-14	-11	N/A
3/31/2022	1	-10	-14	-10	N/A
12/31/2021	1	-9	-14	-10	N/A
9/30/2021	1	-9	-13	-10	N/A
6/30/2021	0	-9	-10	-10	N/A
3/31/2021	0	-11	-9	-9	N/A
12/31/2020	1	-17	-9	-9	N/A
9/30/2020	1	-16	-9	-9	N/A
6/30/2020	1	-15	-8	-8	N/A
3/31/2020	1	-14	-8	-8	N/A
12/31/2019	1	-7	-7	-6	N/A
9/30/2019	1	-8	-6	-6	N/A
6/30/2019	0	-15	-7	-7	N/A
3/31/2019	0	-22	-9	-9	N/A
12/31/2018	0	-24	-9	-9	N/A
9/30/2018	N/A	-24	-8	-8	N/A
6/30/2018	-6	-17	-7	-7	N/A
3/31/2018	-3	-9	N/A	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	4	-5	N/A	-6	N/A
6/30/2017	13	-15	N/A	-8	N/A
3/31/2017	14	-18	N/A	-8	N/A
12/31/2016	15	-21	N/A	-7	N/A
9/30/2016	17	-22	N/A	-7	N/A
6/30/2016	18	-21	N/A	-6	N/A
3/31/2016	19	-22	N/A	-8	N/A
12/31/2015	19	-24	N/A	-9	N/A
9/30/2015	20	-31	N/A	-10	N/A
6/30/2015	21	-26	N/A	-11	N/A
3/31/2015	22	-33	N/A	-15	N/A
12/31/2014	23	-33	N/A	-15	N/A
9/30/2014	23	-22	N/A	-16	N/A
6/30/2014	23	-20	N/A	-15	N/A
3/31/2014	23	-9	N/A	-11	N/A
12/31/2013	22	-8	N/A	-10	N/A
9/30/2013	23	-33	N/A	-9	N/A

Prévisions de croissance des analystes

Earnings vs Savings Rate: 1110 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1110 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1110 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1110's revenue (7.6% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: 1110's revenue (7.6% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Future ROE: Insufficient data to determine if 1110's Return on Equity is forecast to be high in 3 years time

Découvrir les entreprises en croissance

Analyse de l'entreprise et données financières

Données	Dernière mise à jour (heure UTC)
Analyse de l'entreprise	2024/08/21 07:01
Cours de l'action en fin de journée	2024/05/24 00:00
Les revenus	2024/06/30
Revenus annuels	2023/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

Paquet	Données	Cadre temporel	Exemple de source américaine ^*
Finances de l'entreprise	10 ans	Compte de résultat Tableau des flux de trésorerie Bilan	Formulaire 10-K de la SEC Formulaire 10-Q de la SEC
Estimations consensuelles des analystes	+3 ans	Prévisions financières Objectifs de prix des analystes	Rapports de recherche des analystes Blue Matrix
Prix du marché	30 ans	Cours des actions Dividendes, scissions et actions	Données de marché ICE Formulaire S-1 de la SEC
Propriété	10 ans	Actionnaires principaux Délits d'initiés	Formulaire 4 de la SEC Formulaire 13D de la SEC
Gestion	10 ans	L'équipe dirigeante Conseil d'administration	Formulaire 10-K de la SEC Formulaire SEC DEF 14A
Principaux développements	10 ans	Annonces de l'entreprise	Formulaire 8-K de la SEC

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés^.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Sintx Technologies, Inc. est couverte par 7 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

Analyste	Institution
Edward Woo	Ascendiant Capital Markets LLC
David Turkaly	Citizens JMP Securities, LLC
Brandon Folkes	H.C. Wainwright & Co.

Sintx Technologies Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

No longer forecast to breakeven

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Sintx Technologies, Inc. announced that it has received $4.5 million in funding

Sintx Technologies, Inc. Receives Nasdaq Notice Of Non-Compliance With Listing Rule 5550(b)(1)

Sintx Technologies, Inc. Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC Foot & Ankle Implant

Sintx Technologies, Inc. Announces Cessation of Eric Olson as President, Effective March 16, 2026

Sintx Technologies, Inc. Appoints Ryan Elmore as President, Effective March 16, 2026

SINTX Technologies, Inc. Announces Launch of OsseoSculpt an Advanced Biologic for Use with SINAPTIC Foot & Ankle Osteotomy Wedge System

SINTX Technologies, Inc. Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fibrous Materials

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $6.413876 million.

SINTX Technologies, Inc. Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent

Sintx Technologies, Inc. Publishes Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride

SINTX Technologies, Inc. Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates

SINTX Technologies, Inc. Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices

Sintx Technologies, Inc. Announces Executive Appointments

Sintx Technologies, Inc. Announces Board Changes

Sintx Technologies Announces Board Chairman Changes

Sintx Technologies, Inc. announced that it has received $5.000012 million in funding

Tethon Corporation acquired Technology Assessment & Transfer, Inc. from Sintx Technologies, Inc. (NasdaqCM:SINT).

Sintx Technologies, Inc. Appoints Eric K. Olson to the Board of Directors

Sintx Technologies, Inc.Appoints Gregg R. Honigblum as Chief Strategy Officer

Sintx Technologies, Inc., Annual General Meeting, Dec 19, 2024

Sintx Technologies, Inc. Announces Key Executive Promotions: Ryan Bock, Phd, Named Chief Technology Officer and Ann Kutsch Promoted to President of Sintx Ta&T

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million.

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million.

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.11 loss in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Full year 2020 earnings released: US$1.01 loss per share (vs US$4.82 loss in FY 2019)

Sintx Technologies, Inc. Announces the Fabric Technology Shown to Inactivate Upon contact SARS-CoV-2, the Virus Causing the Covid-19 Pandemic